Explore the words cloud of the AML-VACCiN project. It provides you a very rough idea of what is the project "AML-VACCiN" about.
The following table provides information about the project.
|Coordinator Country||Netherlands [NL]|
|Total cost||8˙278˙716 €|
|EC max contribution||6˙001˙482 € (72%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2016-01-01 to 2020-03-31|
Take a look of project's partnership.
|1||STICHTING VUMC||NL (AMSTERDAM)||coordinator||364˙640.00|
|2||BIONTECH INNOVATIVE MANUFACTURING SERVICES GMBH||DE (IDAR OBERSTEIN)||participant||2˙057˙500.00|
|3||IMMATICS BIOTECHNOLOGIES GMBH||DE (TUEBINGEN)||participant||1˙300˙650.00|
|4||LINICAL ACCELOVANCE EUROPE BV||NL ('S-HERTOGENBOSCH)||participant||1˙022˙313.00|
|5||DCPRIME BV||NL (LEIDEN)||participant||495˙150.00|
|6||UNIVERSITETET I BERGEN||NO (BERGEN)||participant||184˙989.00|
|7||ACADEMISCH ZIEKENHUIS GRONINGEN||NL (GRONINGEN)||participant||82˙320.00|
|8||HELSE BERGEN HF*HAUKELAND UNIVERSITY HOSPITAL||NO (BERGEN)||participant||82˙320.00|
|9||HELSINGIN YLIOPISTO||FI (HELSINGIN YLIOPISTO)||participant||82˙320.00|
|10||TECHNISCHE UNIVERSITAET DRESDEN||DE (DRESDEN)||participant||82˙320.00|
|11||UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ||DE (Mainz)||participant||82˙320.00|
|12||UNIVERSITATSKLINIKUM BONN||DE (BONN)||participant||82˙320.00|
|13||UPPSALA UNIVERSITET||SE (UPPSALA)||participant||82˙320.00|
|14||STICHTING VU||NL (AMSTERDAM)||participant||0.00|
Eradicating minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML) is an area of high unmet medical need. AML is a deadly rare disease that affects both children and adults. Approximately 45% of younger AML patients who are treated will be cured, and in older patients (>60 years of age), 85% will relapse and die within 2 years.
Immunotherapy has great potential for treating MRD and dendritic cell (DC) therapy is at the forefront of immunotherapy. The AML-VACCiN consortium takes this to the next level through clinical development of a highly-innovative DC vaccine - DCP-001 - that can be produced off-the-shelf and has a powerful preclinical and clinical profile. The aim is to vaccinate AML patients that have been brought into remission through standard induction or consolidation therapy, and to eradicate MRD and effectively reduce the risk of relapse.
In a clinical Phase I/IIa study, the DCP-001 vaccine has already shown to be safe, non-toxic and capable of inducing an AML-targeted immune response. DCP-001 is designated as an orphan medicinal product in the EU.
The AML-VACCiN consortium will advance the clinical development of the vaccine from early-stage (current status) towards proof of concept for safety and efficacy in a Phase IIb clinical study (intended outcome of this project). In addition, a biomarker program will be developed that enables more effective treatment monitoring, selective patient enrolment in future studies and ultimately personalised AML treatment. The deliverables resulting from this project can be used to assemble a data package to apply for conditional approval in Europe.
AML-VACCiN is the orchestrated action of three innovative companies and internationally renowned top medical scientists representing nine European medical institutes. In line with the IRDiRC objectives, this public-private consortium can bring a powerful AML-vaccine very close to clinical practice.
|Document providing the logo and templates for a uniform corporate look||Other||2020-04-23 02:18:27|
|Communication and dissemination plan||Documents, reports||2020-04-23 02:18:27|
Take a look to the deliverables list in detail: detailed list of AML-VACCiN deliverables.
|year||authors and title||journal||last update|
Arjan A. van de Loosdrecht, Sandra van Wetering, Saskia J. A. M. Santegoets, Satwinder Kaur Singh, Corien M. Eeltink, Yvonne den Hartog, Malika Koppes, Jorn Kaspers, Gert J. Ossenkoppele, Ada M. Kruisbeek, Tanja D. de Gruijl
A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia
published pages: 1505-1518, ISSN: 0340-7004, DOI: 10.1007/s00262-018-2198-9
|Cancer Immunology, Immunotherapy 67/10||2020-04-23|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AML-VACCIN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "AML-VACCIN" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More
Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired PneumoniaRead More